All COVID-19 articles – Page 11
-
NewsClinical trial underway for potential Long COVID treatment
A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca’s long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid.
-
NewsLong COVID biomarkers found – associated with respiratory problems
Researchers have identified biomarkers in the blood associated with symptoms of long COVID, particularly severe respiratory disorders. The discovery can pave the way for future diagnosis and treatment.
-
NewsCOVID-19 vaccinations are metabolically safe, research finds
New research confirms that multiple doses of COVID-19 vaccines do not cause significant metabolic changes, offering reassurance for those concerned about potential long-term side effects of vaccination.
-
NewsBNT162b2 vaccine not only targets COVID-19 virus, but may also help control innate inflammation
New findings suggest the BNT162b2 vaccine may reduce the production of pro-inflammatory mediators to bacterial, fungal or viral infections by reprogramming innate immune cells to regulate inflammation.
-
NewsSuccess of agile COVID-19 pan-Canadian research network highlights how to tackle future pandemics
The operations of CoVaRR-Net, a national interdisciplinary research network initiated to study COVID-19 variants and enhance Canada’s preparedness for future pandemics, have concluded following the expiration of funding.
-
NewsStudy of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients
A study used five analytical methods to show that oral azvudine has a therapeutic effect in elderly COVID-19 patients aged over 60 years.
-
NewsCertain nasal bacteria may boost the risk for COVID-19 infection, study finds
Certain types of nasal bacteria can affect the levels of key proteins the Covid-19 virus needs to enter human cells, offering new insight into why some people are more vulnerable to the disease than others.
-
NewsInvesting in COVID-19 vaccination more than paid off for U.S., study finds
The US national Covid-19 vaccine strategy more than paid for itself after just one year, according to a new study. Because the vaccines reduced how many people developed serious illness or died, the nation saved more money than it spent.
-
NewsCOVID-19 vaccination induces long-lasting antibody B-cell responses
A research study revealed that memory B cells maintain long-lasting and stable responses prior to mRNA vaccinations for COVID-19, but updated vaccines targeting new variants could boost immunity.
-
NewsTackling the ‘silent pandemic’: breakthrough study puts first long COVID treatment on horizon
Researchers have shown a new drug compound can prevent long COVID symptoms in mice – a landmark finding that could lead to a future treatment for the debilitating condition.
-
NewsNew COVID-19 drug shows greater promise against resistant viral strains
A new standalone oral drug candidate has proven to be effective against Paxlovid-resistant COVID-19 strain in animal models. It works with low doses and cause no drug interaction-induced side effects.
-
NewsAI learns to ‘speak’ genetic ‘dialect’ for future SARS-CoV-2 mutation prediction
Researchers have developed a new method to predict mutations in virus protein sequences called Deep Novel Mutation Search (DNMS), a type of artificial intelligence model that uses deep neural networks.
-
NewsmRNA-based COVID-19 vaccines train the ‘long-term memory’ of the innate immune system
A study showed that vaccination of multiple mRNA-based COVID-19 vaccines could induce persistent epigenetic changes in innate immune cells, leading to long-term immune responses for SARS-CoV-2 and other pathogens.
-
News‘It’s a shot, not a vaccine like MMR’: New skepticism prompts call for action
This ‘vaccine is not a vaccine’ is a new, previously unreported type of vaccine-specific scepticism, and it arose only during the COVID-19 pandemic. However, it might, according to the researchers, also apply to the flu vaccine.
-
News‘Low-sugar’ vaccine can provide broad immunity against coronavirus variants
A universal vaccine for coronaviruses removes sugar molecules from an area of a coronavirus spike protein that rarely mutates and creates effective and plentiful antibodies to inactivate the virus.
-
NewsUKHSA highlights pathogens of greatest risk to public health in bid to boost preparedness
The UK Health Security Agency (UKHSA) has today published its view on the pathogen families that could pose the greatest risk to public health, in a bid to focus and guide preparedness efforts against these threats.
-
NewsAntibody-based therapy is several steps closer to treat lethal mucormycosis
A new paper discusses the use of monoclonal antibodies to target a key fungal cell surface protein, CotH, which enables the Mucorales fungus to invade human cells and cause mucormycosis, which has high mortality rates in people with weakened immune systems.
-
NewsMcMaster leads Canada’s first-ever guidelines for Post COVID-19 Condition
A team of experts from McMaster University has led the creation of Canada’s first-ever comprehensive guidelines for diagnosing, managing, preventing, and treating post COVID-19 condition (PCC), more commonly known as long COVID.
-
NewsLong COVID could be causing huge economic burden annually
Behind the healthcare burden from long COVID, a study has also uncovered the economic burden of those who are more likely to suffer from long COVID through a computer simulation model of long COVID probabilities and the accompanied productivity loss.
-
NewsCOVID-19 pandemic worsened mother and infant birth outcomes
Mothers who became pregnant after the start of the pandemic, those who experienced moderate-to-severe infections during pregnancy, and those who had infections during the third trimester were more likely to have adverse outcomes.